这几年IPO越来越难做、监管也越来越严，稍微一个细节没做好，可能就卡在审核环节了。像研发费 用、函证、走访这些基础程序，实际工作中总是被忽视，现在反倒成了监管重点，一不留神就容易踩 坑。 我们整理了近几年的监管案例发现， 研发费用怎么准确归集、函证地址和收件人怎么验证、走访记录 怎么完整留存…… 这些看似没什么技术含量的程序，其实有许多值得重视的细节： 一一一一一一一一、、、、、、、、研研研研研研研研发发发发发发发发费费费费费费费费用用用用用用用用实实实实实实实实务务务务务务务务要要要要要要要要点点点点点点点点及及及及及及及及注注注注注注注注意意意意意意意意事事事事事事事事项项项项项项项项 1、研发项目立项实务要点 3、研发领料实务要点 4、研发样品、样机实务要点 6、研发系统实务要点 二二二二二二二二、、、、、、、、函函函函函函函函证证证证证证证证实实实实实实实实务务务务务务务务要要要要要要要要点点点点点点点点及及及及及及及及注注注注注注注注意意意意意意意意事事事事事事事事项项项项项项项项 1、函证选样实务要点 4、电子函证实务要点 5、替代测试实务要点 三三三三三三三三、、、、、、、、走走走走走走走走访访 ...

Group 1: Company Overview and R&D - The company’s R&D expenses for 2024 are expected to increase by 10% year-on-year, focusing on the development of raw materials and formulations, as well as process optimization and technological innovation for mature products like vitamins [1] - The company has officially started selling para-hydroxyphenol in the PEEK field and is actively promoting its products, having completed sample submissions to major domestic PEEK manufacturers, currently in various validation stages [1] Group 2: Product Registration and Market Activities - The company holds registration certificates for two products: Fumaric Acid Bisoprolol Tablets and Lacosamide Injection, with the former having commenced market promotion and industrialization in 2024 [1] - There are currently no plans for stock incentive programs or share buybacks, although the company previously repurchased shares in 2019 and conducted a restricted stock incentive plan in 2015, along with the first employee stock ownership plan launched in 2021 [2] Group 3: Inventory and Capital Expenditure - The company’s large ending inventory balance is attributed to its diverse business segments, including vitamins, flavors, raw materials, leather chemicals, and chromium salts, consisting mainly of raw materials, work-in-progress, and finished products to meet varying customer demands [2] - Future capital expenditures will primarily focus on new project construction, such as a 600-ton iodinated contrast agent raw material project, and technological upgrades to existing projects aimed at cost reduction, efficiency enhancement, and improved safety and environmental control [2] Group 4: Risk Management - The company has not engaged in hedging activities and currently sees no demand for such services [2]

余承东：华为近十年研发费用为12490亿元 智通财经6月11日电，在华为Pura80系列及全场景新品发布会上，余承东称，华为近十年研发费用为 12490亿元。 ...

Core Insights - Huawei's R&D expenditure over the past decade amounts to 1.249 trillion yuan [1] Group 1 - The launch event featured the Huawei Pura80 series and various new products [1] - Yu Chengdong highlighted the significant investment in research and development by Huawei [1]

Core Viewpoint - The article emphasizes the increasing difficulty of IPOs and the heightened regulatory scrutiny, highlighting the importance of meticulous attention to details in processes such as R&D expense allocation, confirmation letters, and site visits [1]. Group 1: R&D Expense Practical Points - Key points for R&D project initiation include aligning with company strategy, technology trends, and ensuring internal controls are documented [5]. - R&D personnel and hours must be accurately recognized, with special attention to part-time staff contributions reflected in year-end bonuses [5]. - Material input assessments require validation when no BOM (Bill of Materials) is available, and the tracking of R&D samples must be clearly documented [5][16]. Group 2: Confirmation Letter Practical Points - Sample selection for confirmation letters should cover significant amounts, long aging, frequent transactions, and related party transactions [6]. - The content of confirmation letters must be complete, including accounts receivable balances and contract execution progress [6]. - Address verification for recipients is crucial, ensuring that the recipient is a financial or business leader and their identity is confirmed [6][14]. Group 3: Site Visit Practical Points - A site visit plan should be established, including the purpose, target, and timing of the visit [10]. - Background information must be collected prior to the visit, including public and specific transaction information [10]. - During the visit, the identity of reception personnel must be verified, and inventory checks should include photographing serial numbers and production dates [10][11]. Group 4: Course Overview - The course titled "IPO Verification of R&D Expenses, Confirmation Letters, and Site Visit Practices (2025)" will delve into regulatory requirements and practical strategies to navigate the verification process effectively [11][12]. - It will cover the importance of R&D expenses, confirmation letters, and site visits, along with recent regulatory case analyses [12]. - The course will also provide detailed insights into practical points and considerations for each area, ensuring compliance and risk avoidance [17].